IPSEF News and Press, Ipsen Sa Ord From 02/22/23

Ipsen e xtends e xpiration d ate of t ender o ffer for Albireo Pharma , Inc. to 1 March 202 3 Extension a llows for the satisfaction of the HSR Act related condition as o utlined ...

Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive licens e agreement and two new discovery-stage programs Ipsen will now lead all development and commercialization activities of the licensed asset ...

Three-year data – with a median follow-up of 44 months – from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless of IMDC risk score 1 Data represent the longest reported follow-up...

Ipsen S.A. (IPSEY) Q4 2022 Results Conference Call February 09, 2023 07:45 AM ET Company Participants David Loew - CEO Aymeric Le Chatelier - CFO Howard Mayer - Head, Research and Development Conference Call Participants Elizabeth Walton - Credit Suisse ...

2022 total sales up by 8.5% at CER 1 (14.4% as reported) with growth platforms’ 2 sales increasing by 20.9% 1 and Somatuline ® (lanreotide) sales declining by 5.6% 1 2022 core operating margin of 36.9%, broadly in line with 2021; IFRS operating margin of 24.1%,...

Summary The backbone of the Albireo is Bylvay, a product in a platform already approved in one indication and expected to be approved in two significant larger indications. Ipsen recognizes the huge potential and is offering $42 plus a $10 CVR to acquire Albireo. The deal is expected to...

Summary Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only approved life-saving product in a rare pediatric disease market worth $500 mill...

Ipsen to request re-examination of CHMP opinion on palovarotene as a potential treatment for fibrodysplasia ossificans progressiva in E.U. FOP is an ultra-rare disease that continuously and permanently causes abnormal bone formation. 1 There are currently no disease-modifying treatment op...

Investigational Onivyde ® (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine with a manageable safety profile 1 Result...

Transaction focused on Bylvay ® (odevixibat), the first-approved treatment in progressive familial intrahepatic cholestasis in U.S. and E.U., with potential in other rare diseases Acquisition aligned with Ipsen’s long-term strategy for expanding the scope of its Rare Disease p...